Literature DB >> 30155805

Effects of NMDAR Antagonist on the Regulation of P-MARCKS Protein to Aβ1-42 Oligomers Induced Neurotoxicity.

Yudong Liu1, Peng Zhang1, Yabing Zheng2, Chunlin Yang1, Tong Du1, Mengru Ge1, Xiaotian Chang2, Ruisheng Duan1, Guozhao Ma3.   

Abstract

Alzheimer's disease (AD) is a well-known neurodegenerative disease. Deposition of β-amyloid protein (Aβ) oligomers plays a crucial role in the disease progression. Previous studies showed that toxicity induced by Aβ oligomers in cultured neurons and adult rat brain was partially mediated by activation of glutamatergic N-methyl-D-aspartate receptors (NMDAR). Additionally, memantine, a noncompetitive NMDAR antagonist, can significantly improve cognitive functions in some AD patients. However, little is currently known about the potential role of NMDAR antagonist on the regulation of P-MARCKS protein to Aβ1-42 oligomers induced neurotoxicity. The protective effect and mechanism of NMDAR antagonist on primary neurons exposed to Aβ1-42 oligomers were investigated in the study. We have defined that the Aβ1-42 treatment decreased cell viability and increased apoptosis. Moreover, Aβ1-42 oligomers exposure increased P-MARCKS and PIP2 expressions, while decreased SYP expression. However, NMDAR antagonist pretreatment ameliorates Aβ1-42 oligomers induced neuronal apoptosis and partially reverses the expression of P-MARCKS, PIP2 and SYP. In conclusion, NMDAR antagonist may ameliorate neurotoxicity induced by Aβ1-42 oligomers through reducing neuronal apoptosis and protecting synaptic plasticity in rat primary neurons. The mechanism involved may be mediated by the variation of protein P-MARCKS.

Entities:  

Keywords:  Alzheimer’s disease; Aβ1−42 oligomers; Cell apoptosis; P-MARCKS; Synaptic plasticity

Mesh:

Substances:

Year:  2018        PMID: 30155805     DOI: 10.1007/s11064-018-2622-8

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  25 in total

1.  Different forms of MARCKS protein are involved in memory formation in the learning process of imprinting.

Authors:  Revaz O Solomonia; David Apkhazava; Maia Nozadze; Antony P Jackson; Brian J McCabe; Gabriel Horn
Journal:  Exp Brain Res       Date:  2008-05-31       Impact factor: 1.972

Review 2.  Cross-talk unfolded: MARCKS proteins.

Authors:  Anna Arbuzova; Arndt A P Schmitz; Guy Vergères
Journal:  Biochem J       Date:  2002-02-15       Impact factor: 3.857

3.  Amyloid-β effects on synapses and memory require AMPA receptor subunit GluA3.

Authors:  Niels R Reinders; Yvonne Pao; Maria C Renner; Carla M da Silva-Matos; Tessa R Lodder; Roberto Malinow; Helmut W Kessels
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-05       Impact factor: 11.205

4.  Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory.

Authors:  Ganesh M Shankar; Shaomin Li; Tapan H Mehta; Amaya Garcia-Munoz; Nina E Shepardson; Imelda Smith; Francesca M Brett; Michael A Farrell; Michael J Rowan; Cynthia A Lemere; Ciaran M Regan; Dominic M Walsh; Bernardo L Sabatini; Dennis J Selkoe
Journal:  Nat Med       Date:  2008-06-22       Impact factor: 53.440

5.  Protection of Radial Glial-Like Cells in the Hippocampus of APP/PS1 Mice: a Novel Mechanism of Memantine in the Treatment of Alzheimer's Disease.

Authors:  Dayu Sun; Junhua Chen; Xiaohang Bao; Yulong Cai; Jinghui Zhao; Jing Huang; Wei Huang; Xiaotang Fan; Haiwei Xu
Journal:  Mol Neurobiol       Date:  2014-09-09       Impact factor: 5.590

6.  Amyloid Beta Peptides Block New Synapse Assembly by Nogo Receptor-Mediated Inhibition of T-Type Calcium Channels.

Authors:  Yanjun Zhao; Sivaprakash Sivaji; Michael C Chiang; Haadi Ali; Monica Zukowski; Sareen Ali; Bryan Kennedy; Alex Sklyar; Alice Cheng; Zihan Guo; Alexander K Reed; Ravindra Kodali; Jennifer Borowski; Georgia Frost; Patrick Beukema; Zachary P Wills
Journal:  Neuron       Date:  2017-10-11       Impact factor: 17.173

7.  Secreted amyloid β-proteins in a cell culture model include N-terminally extended peptides that impair synaptic plasticity.

Authors:  Alfred T Welzel; John E Maggio; Ganesh M Shankar; Donald E Walker; Beth L Ostaszewski; Shaomin Li; Igor Klyubin; Michael J Rowan; Peter Seubert; Dominic M Walsh; Dennis J Selkoe
Journal:  Biochemistry       Date:  2014-06-24       Impact factor: 3.162

8.  HMGB1, a pathogenic molecule that induces neurite degeneration via TLR4-MARCKS, is a potential therapeutic target for Alzheimer's disease.

Authors:  Kyota Fujita; Kazumi Motoki; Kazuhiko Tagawa; Xigui Chen; Hiroshi Hama; Kazuyuki Nakajima; Hidenori Homma; Takuya Tamura; Hirohisa Watanabe; Masahisa Katsuno; Chiemi Matsumi; Masunori Kajikawa; Takashi Saito; Takaomi Saido; Gen Sobue; Atsushi Miyawaki; Hitoshi Okazawa
Journal:  Sci Rep       Date:  2016-08-25       Impact factor: 4.379

Review 9.  Memantine for the Treatment of Dementia: A Review on its Current and Future Applications.

Authors:  Jaume Folch; Oriol Busquets; Miren Ettcheto; Elena Sánchez-López; Ruben Dario Castro-Torres; Ester Verdaguer; Maria Luisa Garcia; Jordi Olloquequi; Gemma Casadesús; Carlos Beas-Zarate; Carme Pelegri; Jordi Vilaplana; Carme Auladell; Antoni Camins
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

10.  Memantine ER Maintains Patient Response in Moderate to Severe Alzheimer's Disease: Post Hoc Analyses From a Randomized, Controlled, Clinical Trial of Patients Treated With Cholinesterase Inhibitors.

Authors:  George T Grossberg; Gustavo Alva; Suzanne Hendrix; Noel Ellison; Mary C Kane; John Edwards
Journal:  Alzheimer Dis Assoc Disord       Date:  2018 Jul-Sep       Impact factor: 2.703

View more
  2 in total

Review 1.  Potential Therapeutic Benefits of Honey in Neurological Disorders: The Role of Polyphenols.

Authors:  Arslan Iftikhar; Rimsha Nausheen; Humaira Muzaffar; Muhammad Ahsan Naeem; Muhammad Farooq; Mohsin Khurshid; Ahmad Almatroudi; Faris Alrumaihi; Khaled S Allemailem; Haseeb Anwar
Journal:  Molecules       Date:  2022-05-20       Impact factor: 4.927

2.  Pilot proteomic analysis of cerebrospinal fluid in Alzheimer's disease.

Authors:  Justin McKetney; Daniel J Panyard; Sterling C Johnson; Cynthia M Carlsson; Corinne D Engelman; Joshua J Coon
Journal:  Proteomics Clin Appl       Date:  2021-04-26       Impact factor: 3.494

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.